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Abstract
Objectives: this Italian observational study was aimed at collecting data of psychiatric patients with acute episodes
entering General Hospital Psychiatric Wards (GHPWs). Information was focused on diagnosis (DSM-IV), reasons of
hospitalisation, prescribed treatment, outcome of aggressive episodes, evolution of the acute episode.
Methods: assessments were performed at admission and discharge. Used psychometric scales were the Brief Psychiatric
Rating Scale (BPRS), the Modified Overt Aggression Scale (MOAS) and the Nurses' Observation Scale for Inpatient
Evaluation (NOSIE-30).
Results: 864 adult patients were enrolled in 15 GHPWs: 728 (320 M; mean age 43.6 yrs) completed both admission and
discharge visits. A severe psychotic episode with (19.1%) or without (47.7%) aggressive behaviour was the main reason
of admission. Schizophrenia (42.8% at admission and 40.1% at discharge) and depression (12.9% at admission and 14.7%
at discharge) were the predominant diagnoses. The mean hospital stay was 12 days. The mean (± SD) total score of
MOAS at admission, day 7 and discharge was, respectively, 2.53 ± 5.1, 0.38 ± 2.2, and 0.21 ± 1.5. Forty-four (6.0%)
patients had episodes of aggressiveness at admission and 8 (1.7%) at day 7. A progressive improvement in each domain/
item vs. admission was observed for MOAS and BPRS, while NOSIE-30 did not change from day 4 onwards.
The number of patients with al least one psychotic drug taken at admission, in the first 7 days of hospitalisation, and
prescribed at discharge, was, respectively: 472 (64.8%), 686 (94.2%) and 676 (92.9%). The respective most frequently
psychotic drugs were: BDZs (60.6%, 85.7%, 69.5%), typical anti-psychotics (48.3%, 57.0%, 49.6%), atypical anti-psychotics
(35.6%, 41.8%, 39.8%) and antidepressants (40.9%, 48.8%, 43.2%). Rates of patients with one, two or > 2 psychotic drugs
taken at admission and day 7, and prescribed at discharge, were, respectively: 24.8%, 8.2% and 13.5% in mono-therapy;
22.0%, 20.6% and 26.6% with two drugs, and 53.2%, 57.8% and 59.0% with > two drugs. Benzodiazepines were the most
common drugs both at admission (60.0%) and during hospitalisation (85.7%), and 69.5% were prescribed at discharge.
Conclusion: patients with psychiatric diseases in acute phase experienced a satisfactory outcome following intensified
therapeutic interventions during hospitalisation.
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Background
Despite an increasing amount of studies on the epidemi-
ology of acute mental disorders and the availability of
recently introduced pharmacological interventions in the
management of such conditions, only few reports provide
detailed information on the characteristics of psychiatric
patients and treatments received both in the hospital set-
ting and as routine clinical practice [1].
In Italy, a law issued in 1978 stated that all admission of
psychiatric patients had to take place in the General Hos-
pital Psychiatric Wards (GHPWs), thus prohibiting the
admission to Psychiatric Hospitals. From then on, very
few epidemiological studies have been carried out on
inpatient population with psychiatric disorders. Further-
more, most of reports refer to studies performed in local
settings [2-4], which may differ between them in terms of
methods of admission, patients' demographics and socio-
cultural background, and interventions.
GHPWs are psychiatric centres for acute patients with any
psychiatric-related illness, and are located in General Hos-
pitals. Patients remain in GHPWs only during the acute
phase. At discharge, they usually receive therapeutic pre-
scriptions and are no more followed by GHPWs struc-
tures, but they are followed by territorial services, which
are not part of General Hospitals. Little is known about
therapies used in GHPWs.
Recent National epidemiological studies have also shown
that the rates of first admission diagnosis in Italy may dif-
fer from other Western countries [5], and that therapeutic
interventions may depend more on physicians' experi-
ence, common sense and other cultural parameters rather
than on a more rational approach on drug use [6].
Daily living conditions of Italian psychiatric patients, such
as living alone or with relatives, also differ from that of
other countries [7]. Another confounding factor may con-
sist in the evidence that a significant proportion of sub-
jects attending GHPWs are 'self-referred' patients and less
than half admissions are referred by a qualified psychia-
trist [8]. Furthermore, in Italy drug dependent patients are
managed by different medical services independent both
by hospital and territorial services.
Therefore, different Psychiatric Departments' organisation
and the availability of newly introduced drugs (e.g. atypi-
cal antipsychotic) may cause marked differences among
countries, and even among different regions in the same
country, both in terms of diagnosis at admission and dis-
charge, and in terms of therapeutic intervention over time.
Based on the above considerations, to better understand
role and function of GHPWs uniformly distributed across
the National territory, the EPICA ('Gruppo di Studio Epi-
demiologia in Psichiatria Casi Acuti') study group was
aimed at collecting data of adult psychiatric inpatients
entering the study with different diagnosis. Assessment of
effects of interventional measures by using appropriate
and validated psychometric scales was the main objective
of this observational study.
EPICA was a pilot study for the preparation of a more
comprehensive study on GHPWs in Italy, the PERSEO
(Psychiatric EmeRgency Study and EpidemiOlogy) Study.
Patients and methods
Patients and diagnosis
Patients afferent to GHPWs from March 25th 2002 to July
26th 2002 were eligible for the study. Fifteen sites took part
in the study. Patients previously enrolled in this study and
newly admitted to GHPWs were excluded from participa-
tion; however, any new admission was recorded in the
case report form.
Descriptive epidemiology included the analysis of diag-
noses distribution according to DSM-IV and ICD-9, and
the evaluation of social and demographic profile of
patient population, the reason of hospitalisation and the
interventional procedures. Clinical epidemiology was
based on the assessment of prevalence of aggressive epi-
sodes at admission and their incidence in the observa-
tional period; the evolution of the acute psychotic episode
(diagnosis, treatment and outcome) was also evaluated.
The outcome of the acute episode was evaluated in
patients with one of the following group of diagnoses:
schizophrenia, depression, nevrotic disturbance, sub-
stance abuse, psychorganic psychoses, mania, undifferen-
tiated, antisocial and non-antisocial personality disorder.
Observational period
The study design and procedures, including time of assess-
ment, are summarized in Figure 1. The maximal observa-
tional length was 30 days; daily recording of interventions
and outcome was performed in the first 7 days of hospi-
talisation. Visits at Psychiatric Wards were scheduled at
study entry (day 1, admission), at follow-up (day 7) and
at discharge (final visit). On day 30, observation was dis-
continued anyway and assessments of final visit were per-
formed. In patients discharged prior to or at day 7, forms
for final visit were to be completed, without any follow-
up observation. A form for the next 5 hospitalisations fol-
lowing that of the present study was also to be completed.
Psychometric scales
The following psychometric scales were used for assess-
ment: BPRS (Brief Psychiatric Rating Scale), MOAS (Mod-
ified Overt Aggression Scale), and NOSIE-30 (Nurses'
Observation Scale for Inpatient Evaluation).Annals of General Psychiatry 2007, 6:2 http://www.annals-general-psychiatry.com/content/6/1/2
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BPRS is a validated and widely used psychometric scale.
An Italian expanded 24-item version (BPRS version 4.0)
was used in this study [9]. Severity of a total of 24 symp-
toms, grouped in 6 different domains, was evaluated
using a 7-point rating scale ranging from 'not present' to
'extremely severe' to obtain an overall total score. High
levels of inter-rate reliability between experienced (i.e.
psychiatrists and psychologists) and inexperienced opera-
tors (i.e. medical and psychosocial rehabilitation stu-
dents) were shown in previous trials [10]. BPRS version
4.0 was administered at admission, at day 7 and at dis-
charge (or day 30) and forms were completed by physi-
cians following a patient's interview.
The MOAS scale [11] records the forms of aggression and
their severity; it is constituted by 4 subscales based on
increasing severity: verbal aggression, aggression towards
properties, self-aggression, and physical aggression
towards people. Each subscale includes 5 items scored 0-
4; the total score is obtained by multiplying scores of each
subscale by their specific 'weight' (1, 2, 3 and 4, respec-
tively), then adding the 4 obtained values. Subjects with
aggressive behaviours are defined as those having a total
score > 0 in the observational period. MOAS was com-
pleted by non-medical healthcare personnel to assess out-
come or onset of aggressive episodes; it was administered
at admission, at day 2, 3, 4 and 7, and at discharge (or day
30).
The NOSIE-30 [12] was used to assess frequency of 30
behaviours in hospitalised patients, ranging from 'never'
to 'always'. The 30 items are divided in 7 different
domains: social competence, social interest, personal
neatness, irritability, manifest psychosis, retardation and
depression. The first 3 domains reflect positive behav-
ioural dimensions (Total Positive Factors), and the other
4 are indicators of negative behaviours (Total Negative
Factors). The Total Patient Asset score was obtained by the
sum of the positive factors minus the sum of negative fac-
tors and adding 150 as a normalisation factor.
Study organisation
One Local Study Coordinator (LSC) was identified in each
participating site. LSC was responsible for study conduc-
tion and study material distribution; he/she also identi-
fied and properly trained the Clinical Investigators (CI)
and Raters, and ensured their correct application of study
procedures. CIs were responsible for patients' selection
and enrolment, BPRS administration according to proto-
col, completion of case report forms, and contact with
Data Management centre (including quality controls).
Raters were charged of MOAS and NOSIE-30 administra-
tion and correctness.
Data analysis
Data Management, quality control and Statistics were per-
formed by Runtimes srl, Modena (Italy). Results of para-
metric variables were presented as means ± standard
deviation and range, while results of categorical variables
were presented as number and proportions. Evaluable
patients were those completing both the admission and
the discharge visits.
Results
Patients' general characteristics
The general characteristics of patients' populations are
summarised in Table 1. A total of 864 patients were
enrolled in 15 GHPWs and 728 of them (320 males and
408 females) resulted to be evaluable (i.e. had both
admission and discharge visits). The mean age (± standard
Study flow-chart and procedures Figure 1
Study flow-chart and procedures.
DAYS OF HOSPITALISATION  VISITS AND PROCEDURES 
1234567
DISCHARGE  
(or Day 30) 
NEXT ADMISSIONS 
 (maximum 5) 
Study entry  3
Diary of  therapies and interventions  3 3 3 3 3 3 3
Follow-up visit  3
Final visit  3
Diary of next hospitalisations  3
BPRS 3 3 3
MOAS  3 3 3 3 3 3
NOSIE-30  3 3 3Annals of General Psychiatry 2007, 6:2 http://www.annals-general-psychiatry.com/content/6/1/2
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deviation) was 43.6 ± 14.8 years (range 16-99) in the total
population, and was slightly higher in females than in
males. Most of patients were included in the age ranges of
26-34 (164 patients), 35-44 (177 patients), 45-54 (131
patients) and 55-64 (108 patients) years. With regards to
life habits, most of patients were non-alcohol users (402,
55.2%) and non-drug users (602, 82.7%), while more
smokers (385, 52.9%) than non-smokers (291, 40.0%)
took part in the study.
The main reason of admission was a severe psychotic epi-
sode with (139 patients, 19.1%) or without (347, 47.7%)
aggressive behaviour; less frequent reasons included mod-
erate psychoses with unavailability of any caregiver (108,
14.8%) and Axis I disorders with alcohol abuse (56,
7.7%).
The most frequent patients' referrals were the Hospital
emergency department (245, 33.7%), a mental-care cen-
tre (119, 16.3%) and self-referral (103, 14.1%); 429
patients (58.9%) had a known diagnosis at admission.
The mean number of hospitalisations in the previous 12
months was 1.12 ± 2.51.
Hospitalisation and diagnosis
The mean length of hospitalisation was 12.0 ± 10.2 days
(range 1-92); 24.7% of patients stayed in GHPWs for
more than 15 days, 17.9% for 11 to 15 days and 16.9% for
8 to 10 days, while lower rates of patients had a shorter
stay.
Primary diagnoses at admission and discharge are pre-
sented in Figure 2. The most frequent groups of diagnoses
(according to ICD-9) at admission were schizophrenia
(199 patients, 42.8%), depression (60 patients, 12.9%)
and undifferentiated personality disorder (47, 10.1%).
Less frequent diagnoses included mania (40, 8.6%), non-
antisocial personality disorder (33, 7.1%), nevrotic distur-
bance (26, 5.6%), psychorganic psychoses (19, 4.1%),
substance abuse (18, 3.9%) and antisocial personality dis-
order (9, 1.9%). Diagnosis at discharge were schizophre-
nia (268 patients, 40.1%), depression (98 patients,
14.7%), nevrotic disturbance (62, 9.3%), undifferentiated
personality disorder (61, 9.1%), mania (52, 7.8%), non-
antisocial personality disorder (40, 6.0%), psychorganic
psychoses (29, 4.3%), substance abuse (22, 3.3%) and
antisocial personality disorder (15, 2.2%). Diagnosis at
admission was not available in 263 patients (36.1%),
while 59 patients (8.1%) were not diagnosed at discharge.
A total of 59 patients (8.1%) had at least one further hos-
pitalisation after discharge: the mean number of further
admissions was 1.39 ± 0.81 and mean duration was 10.68
± 8.72 days; main reasons were a severe psychotic episode
with (9 patients, 11.0%) or without (40, 48.8%) aggres-
siveness.
Psychometric scales
The number of patients with at least one episode of
aggressiveness was 44 (6.0% of hospitalised) at admission
and progressively declined over time: they were 24 (3.4%)
at day 2, 13 (1.9%) at day 3, 9 (1.4%) at day 4, and 8
(1.7%) at day 7.
Results of MOAS are presented in Figure 3. A marked and
progressive decrease of mean scores from admission to
discharge was observed in total score and in each domain.
Total score was 2.53 ± 5.1 at admission, 0.38 ± 2.2 at day
7 and 0.21 ± 1.5 at discharge; changes of single domains
(verbal aggression, aggression towards properties, self-
aggression, and physical aggression towards people) were
consistent with those of total score.
Figure 4 shows results of BPRS version 4.0. Total score was
62.3 ± 21.2 at admission (day 1), 52.6 ± 20.7 at day 7 and
44.7 ± 17.3 at discharge. A progressive decrease over time
of values recorded at study entry was also observed in each
domain (anxiety-depression, thought disorders, isolation-
motor retardation, hostility-suspiciousness, hyper-reactiv-
ity, and mania) as well as in each of the 24 single items.
Improvements at discharge were observed in each group
of diagnosis (data not shown) and were of similar extent
in all investigated domains.
Results of NOSIE-30 recorded at day 4, day 7 and dis-
charge are presented in Table 2. No clinically relevant
changes were observed in any of the investigated domains
from day 4 to discharge. Among 'positive' domains, a
small increase was observed in social interest, compared
with a small decline in social competence; among 'nega-
tive' domains, all of them (irritability, manifest psychosis,
retardation and depression) showed small improvements
at discharge. Mean values of total patient's asset also did
not change from day 4 to discharge and no changes were
also observed grouping patients by diagnosis.
Therapeutical interventions
Table 3 shows the number of patients with at least one
psychotic drug taken at study entry, during hospitalisation
(day 1, day 4 and day 7) and at discharge.
A number of 472 (64.8%) patients were previously taking
at least one drug at study entry, and this amount increased
from day 1 (90.8%) to day 7 (95.2%); 686 (94.2%)
patients received drug therapy during hospitalisation and
676 (92.9%) had at least one psychotropic drug pre-
scribed at discharge. Monotherapy was administered in
117 patients (24.8%) prior to admission, decreased dur-
ing hospitalisation (13.2% at day 1, 7.2% at day 4 andAnnals of General Psychiatry 2007, 6:2 http://www.annals-general-psychiatry.com/content/6/1/2
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8.2% at day 7), and was prescribed in 91 patients (13.5%)
at discharge, in favour of a more intensive treatment that
included combined therapies with increased frequency.
Rates of patients with two psychotic drugs taken at admis-
sion and day 7, and prescribed at discharge, were, respec-
tively, 22.0%, 20.6% and 26.6%; the corresponding
figures of polytherapy with more than 2 drugs were
53.2%, 57.8% and 59.0%.
As a consequence, the mean number of psychotic drugs
taken simultaneously was 2.6 ± 1.3 prior to admission
and increased to 2.9 ± 1.2 at day 1, 3.2 ± 1.3 at day 4, and
3.3 ± 1.4 at day 7; the mean number at discharge was 2.9
± 1.2.
The most frequently psychotic drug classes taken at study
entry, and prescribed in the first 7 days of hospitalisation
and at discharge, are presented in Table 4. Benzodi-
azepines were the most frequently used drugs at study
entry (60.0% of patients); their administration was inten-
sified during hospitalisation (85.7%) and were prescribed
in 69.5% of patients at discharge. Rates of inpatients
treated with other drugs also increased: typical antipsy-
chotics were taken at study entry and during hospitalisa-
tion in 48.3% and 57.0% of patients, respectively, and
were also prescribed at discharge in 49.6%; the corre-
sponding figures were 35.6%, 41.8% and 39.8% for atyp-
ical antipsychotic drugs, 40.9%, 48.8% and 43.2% for
antidepressants, and 23.9%, 27.1% and 29.1% for mood
stabilizers. Less frequently used other drugs included anti-
dotes for drug of abuse.
In the overall population, the most frequently used drugs
prior to study entry were haloperidol (25.6% of patients),
Table 1: Patients' characteristics
Patient disposition (number and percentages)
No. of enrolled patients 864
No. of patients with admission visit 728 (84.3% of enrolled)
No. of patients with follow-up visit 428 (58.8% of evaluable)
No. of patients with discharge visit 728 (84.3% of enrolled)
Sex (number and percentages)
Males 320 (44.0)
Females 408 (56.0)
Age, years (mean ± SD, range in brackets)
Total population 43.56 ± 14.8 (16-99)
Males 41.74 ± 15.0 (17-99)
Females 44.99 ± 14.5 (16-99)
Age ranges (number and percentages in brackets)
≤25 years 68 (9.3)
26-34 years 164 (22.5)
35-44 years 177 (24.3)
45-54 years 131 (18.0)
55-64 years 108 (14.8)
65-74 years 58 (14.8)
≥75 years 14 (1.9)
NR 8 (1.1)
Weight, kg (mean ± SD, range in brackets) 71.2 ± 17.2 (32-155)
Height, cm (mean ± SD, range in brackets) 167.5 ± 9.2 (140-195)
Alcohol users (number and percentages in brackets)
No 402 (55.2)
Yes, without excess 149 (20.5)
Yes, with excess 135 (18.5)
NR 42 (5.8)
Smoke habits (number and percentages in brackets)
Non-smokers 291 (40.0)
Smokers 385 (52.9)
Ex-smokers 16 (2.2)
NR 36 (4.9)
Substance abuse (number and percentages in brackets)
No 602 (82.7)
Yes 47 (6.5)
Ex-users 30 (4.1)
NR 49 (6.7)
NR: Not recordedAnnals of General Psychiatry 2007, 6:2 http://www.annals-general-psychiatry.com/content/6/1/2
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delorazepam (20.1%) and lorazepam (19.5%); predomi-
nant drugs during hospitalisation were delorazepam
(35.9%), lorazepam (26.7%) and haloperidol (25.4%),
while the most frequently prescribed drug at hospital dis-
charge were haloperidol (26.3%), delorazepam (25.7%)
and olanzapine (21.2%). Predominant combined thera-
pies administered in inpatients were benzodiazepines-
antidepressants (15.6% of patients), atypical drugs-ben-
zodiazepines (14.9%) and benzodiazepines-antidepres-
sants-atypical drugs (9.5%).
Discussion
The main results of this observational study conducted in
15 GHPWs distributed across the whole Italian territory
showed that patients with psychiatric diseases in acute
phase benefited from intensified therapeutical interven-
tions during hospitalisation.
Schizophrenic disorders were the most frequent diagnosis
recorded at entry and accounted for approximately half of
diagnoses. Diagnosis at discharge showed that schizo-
phrenia, depression and nevrotic disorders were all diag-
nosed in an higher proportion of patients compared to
admission. Changes of diagnosis and required treatment
for the acute episode led to pharmaceutical intervention
during hospitalisation and drug prescription at discharge
which was markedly different from that recorded at
admission. However, it can be considered that a signifi-
cant proportion of patients (more than 40% of total eval-
uable sample) had a missing diagnosis at entry, while
only approximately 15% of participating subjects were
not diagnosed at discharge.
Treatment of inpatients included combined therapies in
84.4% of cases at day 7; a therapy with 2 or more drugs
was prescribed in 85.6% of patients at discharge, com-
pared to 75.2% at admission. Treatment or prescription of
combined therapy with 3 or more psychotic drugs also
increased during hospitalisation and at discharge, respec-
tively. With regards to prescription at discharge, BDZs
resulted to be predominant and rates of prescribed
patients increased compared with users at admission;
rates of patients prescribed at discharge with drug of other
classes also increased vs. pre-hospitalisation.
Groups of diagnosis at admission and discharge Figure 2
Groups of diagnosis at admission and discharge. A = Schizophrenia; B = Depression; C = Undifferentiated Personality Disor-
der; D = Mania; E = Non-antisocial Personality Disorder; F = Nevrotic Disturbance; G = Psychorganic Psychosis; H = Sub-
stance Abuse; I = Antisocial Personality Disorder.
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Results of MOAS subscores (values are means, standard deviations in bars); total scores in brackets Figure 3
Results of MOAS subscores (values are means, standard deviations in bars); total scores in brackets.
0
0,2
0,4
0,6
0,8
1
1,2
1,4
Verbal aggression Aggression towards
properties
Self-aggression Physical aggression
s
c
o
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e
Day 1 (2.53)
Day 2 (0.76)
Day 3 (0.54)
Day 4 (0.44)
Day 7 (0.10)
Discharge (0.21)
Table 2: Results of NOSIE-30 (means ± standard deviations).
DOMAINS Day 4 Day 7 Discharge
Social competence 9.0 ± 3.8 8.7 ± 3.8 8.0 ± 3.3
Social interest 10.9 ± 3.6 11.2 ± 3.7 11.8 ± 3.8
Personal neatness 9.4 ± 1.9 9.4 ± 1.9 9.4 ± 1.9
Irritability 10.9 ± 4.9 10.2 ± 4.5 10.2 ± 4.3
Manifest psychosis 5.7 ± 2.5 5.7 ± 2.6 5.2 ± 2.0
Retardation 6.4 ± 2.8 5.9 ± 2.6 5.4 ± 2.3
Depression 5.1 ± 2.3 4.8 ± 1.9 4.6 ± 1.9
TOTAL PATIENT ASSET* 151 ± 8.0 153 ± 7.6 154 ± 7.8
*Total Patient Asset score was obtained by the sum of the positive factors minus the sum of negative factors and adding 150 as a normalisation 
factorAnnals of General Psychiatry 2007, 6:2 http://www.annals-general-psychiatry.com/content/6/1/2
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Intensified interventions led to a satisfactory outcome of
the psychotic acute episode. Aggressiveness, as measured
using MOAS, progressively decreased during hospitalisa-
tion and at discharge compared to admission, as well as
scores of each domain tended to zero (i.e. absence of
aggressiveness) at discharge. Results of BPRS also showed
a progressive decrease over time both of total score and
single domains (and items). Changes of MOAS and BPRS
were observed irrespective of the diagnosis.
Results of NOSIE-30 did not show evidence of changes of
behaviours from day 4 to discharge: according with previ-
ous findings in schizophrenic patients [13], it is likely that
longer periods of observation are required to detect relia-
ble changes. Also, assessments started from day 4 and,
therefore, potential early changes due to interventions
were not measured.
The consumption of psychoactive drugs in Italy (particu-
larly antidepressants) is known to be relatively lower com-
pared to that reported in other countries [14]; this might
be due to cultural or economical factors. However, the
prescription of such drugs is rarely consistent with stand-
ards of treatment recommended by Health authority [15].
A recent survey on the treatment of schizophrenia in Italy
[16] has also shown that polypharmacy and neuroleptics
were administered outside the recommended dose ranges
and durations, and that treatment regimens of the various
Results of BPRS subscores (values are means, standard deviations in bars); total scores in brackets Figure 4
Results of BPRS subscores (values are means, standard deviations in bars); total scores in brackets.
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Table 3: Number of patients (percentage in brackets) with least one psychotic drug taken at study entry, during hospitalisation and at 
discharge.
Study entry Day 1 Day 4 Day 7 Discharge
Patients taking at least one drug 472 (64.8) 661 (90.8) 601 (94.9) 461 (95.2) 676 (92.9)
Monotherapy 117 (24.8) 87 (13.2) 43 (7.2) 38 (8.2) 91 (13.5)
Combination with 2 drugs 104 (22.0) 192 (29.0) 141 (23.5) 95 (20.6) 180 (26.6)
Combination with 3 drugs 128 (27.1) 191 (28.9) 180 (30.0) 132 (28.6) 196 (29.0)
Combination with 4 drugs 89 (18.9) 128 (19.4) 140 (23.3) 110 (23.9) 142 (21.0)
Combination with > 4 drugs 34 (7.2) 50 (7.6) 65 (10.8) 52 (11.3) 61 (9.0)
Mean number of drugs (± SD) 2.6 ± 1.3 2.9 ± 1.2 3.2 ± 1.3 3.3 ± 1.4 2.9 ± 1.2Annals of General Psychiatry 2007, 6:2 http://www.annals-general-psychiatry.com/content/6/1/2
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drug classes diverged on the basis of patients' age, popula-
tion density and geographical area. For example, patients
treated with atypical antipsychotic drugs are mainly
younger than those receiving other drug classes and poly-
therapy is more frequently prescribed in patients receiving
typical antipsychotic drugs [16]; furthermore, prescription
of antidepressants in Southern Italy is lower than that in
the rest of the country [17]. This study was designed to
obtain an overall overview in terms of diagnosis and
effects of therapy, regardless of location and trend of treat-
ment in individual sites; however, results seem to confirm
a sub optimal treatment of psychiatric outpatients. Diag-
nosis at entry was also missing in a relevant amount of
patients, mainly because of the prioritisation to symp-
toms relief, postponing diagnosis after patient was stabi-
lised.
Onset of acute episodes might also bee due to a lack of
compliance to prescribed drug regimens: it is well recog-
nised that the administered dose in a domiciliary setting
is often much less than prescribed or even omitted at all
[18]. Therefore, treatment of inpatients is useful to avoid
problems of misuse and to adopt therapies according with
a more precise diagnosis.
The pattern of use of antipsychotic drugs is greatly
changed in recent years, particularly after the introduction
of atypical drugs, and emerging trends towards an intensi-
fied drug dosing and polytherapy have been described
worldwide [19]. Findings of this study are consistent with
this current trend in use of antipsychotics on inpatients
basis.
The General Hospital Psychiatric Wards setting is the
structure suitable for the treatment of acute psychiatric
cases; more rational and intensified use of psychotropic
drugs can be recommended to achieve a rapid and favour-
able response to therapy. Since antipsychotics were the
most widely used drugs in acute hospitalization phase,
the availability of newer formulations with faster onset of
action and better safety profile offered by atypical drugs,
which were not yet in use at the time of this study, will
allow advances in pharmacological treatment.
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